Výsledky vyhledávání - "Giuseppe Fatuzzo"

Targeted therapy for thymic epithelial tumors: a new horizon? Review of the literature and two cases reports

Autor: Giuseppe Fatuzzo, Matteo Simonelli, Luca Rubino, Marco Alloisio, Armando Santoro, Paolo Andrea Zucali, Elena Lorenzi, Matteo B. Suter

Publikováno v: Future oncology (London, England). 11(8)

ABSTRACT Surgical resection remains the cornerstone of therapy for early-stage thymic epithelial tumors (TETs), while in advanced or recurrent forms, a multimodality approach incorporating radiation and chemotherapy is required. Given the absence of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f100885fd67939754a402a293ef1c83
https://pubmed.ncbi.nlm.nih.gov/25832879

Zobrazit plný text záznamu

Report on the 40th annual meeting of the European society for blood and marrow transplantation

Autor: Giuseppe, Fatuzzo

Publikováno v: ecancermedicalscience

Introduction The EBMT is a non-profit scientific society representing 563 transplant centres from 57 countries in and outside Europe. Background From 29 March to 2 April 2014, the EBMT Annual Meeting took place at the Milan Convention Centre (MiCo),

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::48c68a5847ff894149d6d6b0844b0eed
https://pubmed.ncbi.nlm.nih.gov/24963347

Zobrazit plný text záznamu

Tivantinib in combination with Carboplatin and Pemetrexed as first line treatment in patients with advanced non-squamous NSCLC or Malignant Pleural Mesothelioma: results of phase I trial

Autor: Monica Bertossi, F. De Vincenzo, Chiara Miggiano, C. Bonifacio, Paolo Andrea Zucali, Matteo Simonelli, Antonella Santoro, F. Mrakic Sposta, Laura Giordano, Matteo Perrino, Giuseppe Fatuzzo

Publikováno v: Annals of Oncology. 26:vi78

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bedbc49f04bfed11d7058f47695334e2
https://doi.org/10.1093/annonc/mdv343.18

Zobrazit plný text záznamu

Phase I trial of tivantinib in combination with carboplatin and pemetrexed as first-line treatment in patients with advanced nonsquamous non small cell lung cancer or malignant pleural mesothelioma

Autor: Chiara Miggiano, Cristiana Bonifacio, Monica Bertossi, Federica Mrakic Sposta, Paolo Andrea Zucali, Giuseppe Fatuzzo, Armando Santoro, Fabio De Vincenzo, Matteo Simonelli, Matteo Perrino, Laura Giordano

Publikováno v: Journal of Clinical Oncology. 33:2549-2549

2549 Background: Tivantinib (T) is a selective non-ATP competitive oral inhibitor of MET receptor. Preclinical data showed that MET inhibition blocks Malignant Pleural Mesothelioma (MPM) and Non Sm...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::088427dcca0379d67173d83f1aad90a6
https://doi.org/10.1200/jco.2015.33.15_suppl.2549

Zobrazit plný text záznamu

Phase I-Ib trial of tivantinib in combination with carboplatin and pemetrexed as first-line treatment in patients (pts) with advanced nonsquamous NSCLC or malignant pleural mesothelioma (MPM)

Autor: Matteo Simonelli, Giuseppe Fatuzzo, Armando Santoro, Monica Bertossi, Matteo Perrino, Fabio De Vincenzo, Laura Giordano, Matteo B. Suter, Paolo Andrea Zucali

Publikováno v: Journal of Clinical Oncology. 32:TPS7610-TPS7610

TPS7610 Background: Dysregulation of MET signalling has been reported as a key event in several malignancies and has been identified as a promising therapeutic target. Strong preclinical data on MP...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f0bcf4cd172dce6409ba650f8a131050
https://doi.org/10.1200/jco.2014.32.15_suppl.tps7610

Zobrazit plný text záznamu

Akademický článek

Report on the 40th Annual Meeting of the European Society for Blood and Marrow Transplantation.

Autor: Fatuzzo, Giuseppe¹ giuseppe.fatuzzo2@gmail.com

Publikováno v: Ecancermedicalscience. 2014, Vol. 8 Issue 413-446, p1-4. 4p.

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání